Prodrug applications for targeted cancer therapy

AAPS Journal

Volumn 16, Issue 5, 2014, Pages 899-913

  Giang, Irene ^a   Boland, Erin L ^a,b   Poon, Gregory M K ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; complementation; conditional bispecificity; prodrugs; targeted therapy

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5 O LYSYL FLOXURIDINE; ANTHRAX TOXIN; ANTIBODY CONJUGATE; BCCA 621C; CATHEPSIN; CELL SURFACE RECEPTOR; CYTARABINE; DOXORUBICIN; EVOFOSFAMIDE; FLOXURIDINE DERIVATIVE; FLUCYTOSINE; FLUOROURACIL; FOLATE RECEPTOR; FOLIC ACID; GEMCITABINE; IC 86621; LEGUMAIN; MACROGOL; MATRIX METALLOPROTEINASE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NANOPARTICLE; PRODRUG; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN SERINE THREONINE KINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTINEOPLASTIC AGENT; ENZYME; RECOMBINANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; DRUG CONJUGATION; DRUG EFFICACY; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MACROMOLECULE; MEDICINAL CHEMISTRY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PHOTODYNAMIC THERAPY; PROTEIN CLEAVAGE; RADIOSENSITIVITY; REVIEW; TREND STUDY; TUMOR MICROENVIRONMENT; ANIMAL; BIOTRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; METABOLISM; NEOPLASMS; PATHOLOGY; PROTEIN ENGINEERING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DRUG DESIGN; ENZYMES; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRODRUGS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84908356062     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9638-z     Document Type: Review

References (100)

1. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003;138(10):819-30. doi:10.7326/0003-4819-138-10-200305200- 00010. (Pubitemid 38124644)
2. Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem. 2008;15(18):1802-26. doi:10.2174/092986708785132997.
3. Han HK, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS Pharmsci. 2000;2(1).
4. Silva AT, Chung MC, Castro LF, Guido RV, Ferreira EI. Advances in prodrug design. Mini Rev Med Chem. 2005;5(10):893-914. (Pubitemid 41300737)
5. Kratz F, Müller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem. 2008;3(1):20-53. doi:10.1002/cmdc. 200700159.
6. Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev. 2011;63(8):659-70. doi:10.1016/j.addr.2011.02. 002.
7. Choi KY, Swierczewska M, Lee S, Chen X. Protease-activated drug development. Theranostics. 2012;2(2):156-78. doi:10.7150/thno.4068.
8. Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, Isaacs JT. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 1998;58(12):2537-40. (Pubitemid 28275422)
9. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003;95(13):990-1000. doi:10.1093/jnci/95.13.990. (Pubitemid 36896716)
10. Albright CF, Graciani N, Han W, Yue E, Stein R, Lai Z, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther. 2005;4(5):751-60. doi:10.1158/1535-7163.mct-05-0006. (Pubitemid 40767119)
11. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev. 2004;56(8):1055-8. doi:10.1016/j.addr.2004.02.003. (Pubitemid 38496506)
12. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, et al. Aminopeptidase N is a receptor for tumorhoming peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60(3):722-7. (Pubitemid 30094573)
13. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91. doi:10.1038/Nrc727.
14. Landowski CP, Vig BS, Song X, Amidon GL. Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary fl oxuridine amino acid ester prodrugs. Mol Cancer Ther. 2005;4(4):659-67. doi:10.1158/1535-7163.MCT- 04-0290. (Pubitemid 40601848)
15. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21(1):5- 13. doi:10.1021/bc9002019.
16. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with Trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-90. doi:10.1158/0008-5472.can-08-1776.
17. Seymour LW, Ulbrich K, Wedge SR, Hume IC, Strohalm J, Duncan R. N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. Br J Cancer. 1991;63(6):859-66.
18. Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, et al. Target speci fic and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release . 2010;141(1):2-12. doi:10.1016/j.jconrel.2009.09.010.
19. Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, Höidén-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66(8):4339-48. doi:10.1158/0008-5472.can-05-3521.
20. Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariepy J. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009;37(3):866-76. doi:10.1093/nar/gkn967.
21. Danson S, Ward TH, Butler J, Ranson M. DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev. 2004;30(5):437-49. doi:10.1016/j.ctrv.2004. 01.002. (Pubitemid 38968124)
22. Hargreaves RH, Hartley JA, Butler J. Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. Front Biosci. 2000;5:E172-80.
23. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet. 2001;10(7):677-85. doi:10.1093/hmg/10.7.677. (Pubitemid 32331575)
24. Polvani S, Calamante M, Foresta V, Ceni E, Mordini A, Quattrone A, et al. Acycloguanosyl 5′-thymidyltriphosphate, a thymidine analogue prodrug activated by telomerase, reduces pancreatic tumor growth in mice. Gastroenterology. 2011;140(2):709-20.e9. doi:10.1053/j.gastro.2010.10.050.
25. Bennewith KL, Dedhar S. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer. 2011;11:504. doi:10.1186/1471-2407-11-504.
26. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393-410. http://www.nature.com/nrc/journal/v11/n6/suppinfo/nrc3064- S1.html.
27. Bouquet F, Ousset M, Biard D, Fallone F, Dauvillier S, Frit P, et al. A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia. J Cell Sci. 2011;124(Pt 11):1943-51. doi:10.1242/jcs.078030.
28. Lindquist Kirstin E, Cran Jordan D, Kordic K, Chua Peter C, Winters Geoffrey C, Tan Jason S, et al. Selective radiosensitization of hypoxic cells using BCCA621C: a novel hypoxia activated prodrug targeting DNA-dependent protein kinase. Tumor Microenviron Ther. 2013;1:46. doi:10.2478/tumor-2013-0003.
29. Portwood S, Lal D, Hsu Y-C, Vargas R, Johnson MK, Wetzler M, et al. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models. Clin Cancer Res. 2013. doi:10.1158/1078-0432.ccr-13- 0674.
30. Bhargava A, Vaishampayan UN. Satraplatin: leading the new generation of oral platinum agents. Expert Opin Investig Drugs. 2009;18(11):1787-97. doi:10.1517/13543780903362437.
31. Mukhopadhyay S, Barnés CM, Haskel A, Short SM, Barnes KR, Lippard SJ. Conjugated platinum(IV) - peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem. 2007;19(1):39-49. doi:10.1021/bc070031k. (Pubitemid 351213833)
32. Yamamoto N, Renfrew AK, Kim BJ, Bryce NS, Hambley TW. Dual targeting of hypoxic and acidic tumor environments with a cobalt (III) chaperone complex. J Med Chem. 2012;55(24):11013-21. doi:10.1021/jm3014713.
33. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000;60(14):3813-22. (Pubitemid 32204573)
34. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46(10):5276-81. (Pubitemid 16008301)
35. Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol. 1998;55(10):1673-81. doi:10.1016/S0006-2952(98) 00034-3. (Pubitemid 28223460)
36. Hazra S, Sabini E, Ort S, Konrad M, Lavie A. Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. Biochemistry. 2009;48(6):1256-63. doi:10.1021/bi802062w.
37. Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther. 2007;15(5):962-70. doi:10.1038/mt.sj.6300122. (Pubitemid 46621655)
38. Vernejoul F, Ghenassia L, Souque A, Lulka H, Drocourt D, Cordelier P, et al . Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther. 2006;14(6):758-67. (Pubitemid 44743131)
39. Kerr DE, Senter PD, Burnett WV, Hirschberg DL, Hellstrom I, Hellstrom KE. Antibodypenicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother. 1990;31(4):202-6. (Pubitemid 20222428)
40. Yoon KJ, Qi J, Remack JS, Virga KG, Hatfield MJ, Potter PM, et al. Development of an etoposide prodrug for dual prodrugenzyme antitumor therapy. Mol Cancer Ther. 2006;5(6):1577-84. doi:10.1158/1535-7163.MCT-06-0090. (Pubitemid 44070495)
41. Phelan RM, Ostermeier M, Townsend CA. Design and synthesis of a β-lactamase activated 5-fluorouracil prodrug. Bioorg Med Chem Lett. 2009;19(4):1261-3. doi:10.1016/j.bmcl.2008.12.057.
42. Tietze LF, Schmuck K. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. Curr Pharm Des. 2011;17(32):3527-47.
43. Aboody KS, Najbauer J, Metz MZ, D'Apuzzo M, Gutova M, Annala AJ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med. 2013;5(184):184ra59. doi:10.1126/scitranslmed.3005365.
44. Umer B, Good D, Anne J, Duan W, Wei MQ. Clostridial spores for cancer therapy: targeting solid tumour microenvironment. J Toxicol. 2012;2012:862764. doi:10.1155/2012/862764.
45. Massa PE, Paniccia A, Monegal A, de Marco A, Rescigno M. Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. Blood. 2013;122(5):705-14. doi:10.1182/blood-2012- 12-474098.
46. Fan J, Zeng F, Xu J, Wu S. Targeted anti-cancer prodrug based on carbon nanotube with photodynamic therapeutic effect and pH-triggered drug release. J Nanoparticle Res. 2013;15(9):1-15. doi:10.1007/s11051-013-1911-z.
47. Min Y, Li J, Liu F, Yeow EK, Xing B. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles. Angew Chem Int Ed Engl. 2013. doi:10.1002/anie.201308834.
48. Barenholz Y. Doxil® - the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-34. doi:10.1016/j.jconrel.2012.03. 020.
49. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387-92. (Pubitemid 17221789)
50. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422(6927):37-44. doi:10.1038/nature01451. (Pubitemid 36323287)
51. Li C, Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev. 2008;60(8):886-98. doi:10.1016/j.addr.2007.11.009.
52. Wong AD, DeWit MA, Gillies ER. Amplified release through the stimulus triggered degradation of self-immolative oligomers, dendrimers, and linear polymers. Adv Drug Deliv Rev. 2012;64(11):1031-45. doi:10.1016/j.addr.2011.09. 012.
53. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ. Targeted single-wall carbon nanotube mediated Pt(IV) prodrug delivery using folate as a homing device. J Am Chem Soc. 2008;130(34):11467-76.
54. Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc. 2007;129(27):8438-9. doi:10.1021/ ja073231f. (Pubitemid 47066504)
55. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356-61. doi:10.1073/pnas.0809154105.
56. Zhang G, Zhang M, He J, Ni P. Synthesis and characterization of a new multifunctional polymeric prodrug paclitaxel-polyphosphoester-folic acid for targeted drug delivery. Polym Chem. 2013;4(16):4515-25. doi:10.1039/c3py00419h.
57. Jung BY, Jeong YC, Min JH, Kim JE, Song YJ, Park JK, et al. Tumor-binding prodrug micelles of polymer-drug conjugates for anticancer therapy in HeLa cells. J Mater Chem. 2012;22(18):9385-94. doi:10.1039/C2jm30534h.
58. Jensen SS, Andresen TL, Davidsen J, Høyrup P, Shnyder SD, Bibby MC, et al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther. 2004;3(11):1451-8. (Pubitemid 39562590)
59. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398-405. doi:10.1158/1078-0432.ccr-11-0487.
60. Ogata M, Fryling CM, Pastan I, FitzGerald DJ. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem. 1992;267(35):25396-401.
61. Hervent AS, De Keulenaer GW. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci. 2012;13(10):12268-86. doi:10.3390/ijms131012268.
62. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? mAbs. 2009;1(6):539-47.
63. Verheije MH, Rottier PJ. Retargeting of viruses to generate oncolytic agents. Adv Virol. 2012;2012:798526. doi:10.1155/2012/798526.
64. Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res. 2007;13(21):6486 - 93. doi:10.1158/1078-0432.ccr-07-0938.
65. Oh S, Stish BJ, Vickers SM, Buchsbaum DJ, Saluja AK, Vallera DA. A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas. 2010;39(6):913-22. doi:10.1097/MPA.0b013e3181cbd908.
66. Poon GM. Quantitative analysis of affinity enhancement by noncovalently oligomeric ligands. Anal Biochem. 2013;433(1):19-27. doi:10.1016/j.ab.2012.10. 005.
67. Young JA, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem. 2007;76:243-65. doi:10.1146/annurev.biochem.75.103004.142728.
68. Ascenzi P, Visca P, Ippolito G, Spallarossa A, Bolognesi M, Montecucco C. Anthrax toxin: a tripartite lethal combination. FEBS Lett. 2002;531(3):384-8. doi:10.1016/S0014-5793(02)03609-8. (Pubitemid 35336056)
69. Kintzer AF, Thoren KL, Sterling HJ, Dong KC, Feld GK, Tang II, et al. The protective antigen component of anthrax toxin forms functional octameric complexes. J Mol Biol. 2009;392(3):614-29. doi:10.1016/j.jmb.2009.07.037.
70. Abrami L, Liu S, Cosson P, Leppla SH, van der Goot FG. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol. 2003;160(3):321-8. doi:10.1083/jcb. 200211018. (Pubitemid 36182723)
71. Miller CJ, Elliott JL, Collier RJ. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry. 1999;38(32):10432-41. doi:10.1021/bi990792d.
72. Arora N, Klimpel KR, Singh Y, Leppla SH. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem. 1992;267(22):15542-8.
73. Arora N, Leppla SH. Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect Immun. 1994;62(11):4955-61. (Pubitemid 24332801)
74. Blanke SR, Milne JC, Benson EL, Collier RJ. Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen. Proc Natl Acad Sci U S A. 1996;93(16):8437-42. (Pubitemid 26269576)
75. McCluskey AJ, Collier RJ. Receptor-directed chimeric toxins created by sortase-mediated protein fusion. Mol Cancer Ther. 2013;12(10):2273-81. doi:10.1158/1535-7163.MCT-13-0358.
76. McCluskey AJ, Olive AJ, Starnbach MN, Collier RJ. Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen. Mol Oncol. 2013;7(3):440-51. doi:10.1016/j.molonc.2012.12.003.
77. Mechaly A, McCluskey AJ, Collier RJ. Changing the receptor specificity of anthrax toxin. MBio. 2012;3(3):e00088-12. doi:10.1128/mBio.00088-12.
78. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A. 2003;100(2):657-62. doi:10.1073/pnas.0236849100. (Pubitemid 36126108)
79. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem. 2001;276(21):17976 - 84. doi:10.1074/jbc.M011085200.
80. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res. 2000;60(21):6061-7.
81. Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, et al. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem. 2008;283(1):529-40. doi:10.1074/jbc.M707419200.
82. Abi-Habib RJ, Singh R, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol Cancer Ther. 2006;5(10):2556-62. doi:10.1158/1535-7163.MCT-06-0315. (Pubitemid 44650920)
83. Liu S, Redeye V, Kuremsky JG, Kuhnen M, Molinolo A, Bugge TH, et al. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin. Nat Biotechnol. 2005;23(6):725-30. doi:10.1038/nbt1091. (Pubitemid 41716363)
84. Phillips DD, Fattah RJ, Crown D, Zhang Y, Liu S, Moayeri M, et al. Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors. J Biol Chem. 2013;288(13):9058-65. doi:10.1074/jbc.M113.452110.
85. Pentelute BL, Sharma O, Collier RJ. Chemical dissection of protein translocation through the anthrax toxin pore. Angew Chem Int Ed Engl. 2011;50(10):2294-6. doi:10.1002/anie.201006460.
86. Pentelute BL, Barker AP, Janowiak BE, Kent SB, Collier RJ. A semisynthesis platform for investigating structure-function relationships in the N-terminal domain of the anthrax Lethal Factor. ACS Chem Biol. 2010;5(4):359 - 64. doi:10.1021/cb100003r.
87. Yamada S, Kuroda T, Fuchs BC, He X, Supko JG, Schmitt A, et al. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther. 2012;19(3):160-70. doi:10.1038/cgt.2011.70.
88. Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, et al. Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. Br J Cancer. 2012;106(3):496-507. doi:10.1038/bjc.2011.577.
89. Boland EL, Van Dyken CM, Duckett RM, McCluskey AJ, Poon GM. Structural complementation of the catalytic domain of Pseudomonas exotoxin A. J Mol Biol. 2014;426(3):645-55. doi:10.1016/j.jmb.2013.11.002.
90. Dong Z, Nor JE. Transcriptional targeting of tumor endothelial cells for gene therapy. Adv Drug Deliv Rev. 2009;61(7-8):542-53. doi:10.1016/j.addr.2009. 02.006.
91. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv Drug Deliv Rev. 2009;61(7-8):572-88. doi:10.1016/j.addr. 2009.03.014.
92. Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol. 2003;2003(2):110-37. doi:10.1155/S1110724303209074. (Pubitemid 36828265)
93. Galarneau A, Primeau M, Trudeau LE, Michnick SW. Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein interactions. Nat Biotechnol. 2002;20(6):619-22. doi:10.1038/nbt0602-619. (Pubitemid 34595158)
94. Ulbrich K, Etrych T, Chytil P, Jelinkova M, Rihova B. HPMA copolymers with pH controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. J Control Release. 2003;87(1-3):33-47. (Pubitemid 36258386)
95. Chandran SS, Nan A, Rosen DM, Ghandehari H, Denmeade SR. A prostate-specific antigen-activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Mol Cancer Ther. 2007;6(11):2928-37. doi:10.1158/1535-7163.mct-07-0392. (Pubitemid 350206771)
96. Huang B, Desai A, Tang S, Thomas TP, Baker JR. The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release. Org Lett. 2010;12(7):1384-7. doi:10.1021/ol1002626.
97. de Groot FM, Broxterman HJ, Adams HP, van Vliet A, Tesser GI, Elderkamp YW, et al. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrintargeted plasmin-cleavable doxorubicin prodrug. Mol Cancer Ther. 2002;1(11):901-11.
98. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458-65. doi:10.1182/blood- 2003-01-0039. (Pubitemid 36988057)
99. Sanderson RJ, Hering MA, James SF, Sun MMC, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2):843-52. (Pubitemid 40116913)
100. Omelyanenko V, Gentry C, Kopečková P, Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer. 1998;75(4):600-8. doi:10.1002/(SICI)1097-0215(19980209)75:4〈600::AID-IJC18〉3.0.CO;2-C. (Pubitemid 28094108)